This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Phibro Animal Health (PAHC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PAHC or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -22.25% in 4 Weeks
by Zacks Equity Research
Phibro (PAHC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Phibro (PAHC) is Poised for a Turnaround After Losing -13.52% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Phibro (PAHC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
InMode (INMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Here is Why Growth Investors Should Buy Phibro (PAHC) Now
by Zacks Equity Research
Phibro (PAHC) could produce exceptional returns because of its solid growth attributes.
Top 3 MedTech Stocks to Weather the Trump Tariff Turbulence
by Sridatri Sarkar
In the present market turbulence, investors may want to consider discounted stocks, such as FMS, PAHC and COR.
Is it the Right Time to Add EYE Stock to Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts. Positive industry trends should also favor its growth.
Reasons to Retain Penumbra Stock in Your Portfolio for Now
by Zacks Equity Research
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts.
Why Phibro Animal Health (PAHC) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Add ABT Stock to Your Portfolio Right Now
by Zacks Equity Research
Investors feel optimistic about Abbott's robust strength in the EPD, Diabetes and Nutrition businesses. However, unfavorable forex impacts are concerning.
Is it Worth Retaining Thermo Fisher Stock in Your Portfolio Now?
by Zacks Equity Research
TMO continues to hold on to investors' attention due to its value-added acquisitions and trusted end-market channels.
PAHC vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. BSX: Which Stock Is the Better Value Option?
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Myriad Genetics Stock Worth Holding in Your Portfolio Now?
by Zacks Equity Research
Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.
Prestige Consumer Gains 17.1% in a Year: What's Driving the Stock?
by Zacks Equity Research
PBH's shares rise on the back of its portfolio of consumer brands and focus on core strategies to achieve long-term success.
Should You Retain Exact Sciences Stock in Your Portfolio Now?
by Zacks Equity Research
EXAS' solid focus on advancing new solutions bodes well for investors. However, a dull macroeconomic condition adds to the worry.
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
HCI Group and Boise Cascade have been highlighted as Zacks Bull and Bear of the Day.
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally
by Urmimala Biswas
Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD.
Should You Bet on PAHC Stock at a Discounted P/E of 10.41X?
by Moumi Mondal
PAHC's solid MFA franchise, now bolstered by Zoetis' portfolio, makes it a solid investment case. A well-established foothold in key regions is also a factor.
Should You Consider Retaining PBH Stock in Your Portfolio Now?
by Zacks Equity Research
Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.
Looking for a Growth Stock? 3 Reasons Why Phibro (PAHC) is a Solid Choice
by Zacks Equity Research
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.